Onconova Therapeutics(ONTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights Merger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond · Lead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in ...